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Abstract
Background: Partial factorial trials compare two or more pairs of treatments on overlapping patient groups, randomising
some (but not all) patients to more than one comparison. The aims of this research were to compare different methods
for conducting and analysing economic evaluations on partial factorial trials and assess the implications of considering
factors simultaneously rather than drawing independent conclusions about each comparison.
Methods: We estimated total costs and quality-adjusted life years (QALYs) within 10 years of surgery for 2252 patients in
the Knee Arthroplasty Trial who were randomised to one or more comparisons of different surgical types. We compared
three analytical methods: an “at-the-margins” analysis including all patients randomised to each comparison (assuming no
interaction); an “inside-the-table” analysis that included interactions but focused on those patients randomised to two
comparisons; and a Bayesian vetted bootstrap, which used results from patients randomised to one comparison as priors
when estimating outcomes for patients randomised to two comparisons. Outcomes comprised incremental costs, QALYs
and net benefits.
Results: Qualitative interactions were observed for costs, QALYs and net benefits. Bayesian bootstrapping generally
produced smaller standard errors than inside-the-table analysis and gave conclusions that were consistent with at-the-
margins analysis, while allowing for these interactions. By contrast, inside-the-table gave different conclusions about
which intervention had the highest net benefits compared with other analyses.
Conclusions: All analyses of partial factorial trials should explore interactions and assess whether results are sensitive to
assumptions about interactions, either as a primary analysis or as a sensitivity analysis. For partial factorial trials closely
mirroring routine clinical practice, at-the-margins analysis may provide a reasonable estimate of average costs
and benefits for the whole trial population, even in the presence of interactions. However, such conclusions will
be misleading if there are large interactions or if the proportion of patients allocated to different treatments differs
markedly from what occurs in clinical practice. The Bayesian bootstrap provides an alternative to at-the-margins
analysis for analysing clinical or economic endpoints from partial factorial trials, which allows for interactions
while making use of the whole sample. The same techniques could be applied to analyses of clinical endpoints.
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Background
Full factorial trials randomise all patients to any combin-
ation of two or more treatments: e.g. A, B, both or neither.
Partial factorial trials1 also evaluate multiple treatments
simultaneously on the same patient group, but randomise
only a subset of patients to two or more factors, while other
patients are randomised to just one factor or to a different
combination of factors [1–3]. For example, a full factorial
trial may randomise all patients to drug A or its placebo
and simultaneously to drug B or its placebo, while a partial
factorial trial may randomise some patients to drug A or its
placebo, randomise some to drug B or its placebo and
randomise other patients simultaneously to A or its
placebo and to B or its placebo (Table 1). High-profile
examples of this design include the Women’s Health
Initiative [2] and the United Kingdom Prospective Diabetes
Study (UKPDS) [4].
By comparing multiple treatment factors on overlapping
populations, partial factorial trials can address multiple
questions in the same study, reducing the fixed costs of
each research question and the overall sample size com-
pared with conducting several non-overlapping trials. Since
some patients are randomised to two or more factors in a
factorial manner, partial factorial trials can also investigate
interactions: i.e. whether the effect of A differs depending
on whether B is also given. Partial factorial designs are often
used when economic, geographic or clinical constraints
restrict the comparisons to which patients can be ran-
domised [1]. In particular, this design facilitates flexible
recruitment strategies, such as letting patients [2] or clini-
cians [5] choose which comparisons to be randomised into,
or recruiting only patients from certain countries [6] or those
with specific comorbidities, clinical characteristics or labora-
tory findings to a second (or even third) comparison [2, 7].
While there is extensive research and established guide-
lines on full factorial trials, to date only one review article
has discussed partial factorial trials [1]. Partial factorial
trials raise several additional issues over and above those
introduced by full factorial designs, and the appropriate
analytical methods are less clear and under-researched.
As well as evaluating the “main effects” of each factor,
it is also informative to estimate the magnitude of interac-
tions and evaluate the impact of interactions on the con-
clusions, particularly for economic endpoints. Increasing
numbers of economic evaluations are conducted alongside
randomised trials [8, 9]. Recent work has suggested that
interactions between treatments are particularly likely
to arise for economic endpoints [10, 11]. This work also
demonstrated the importance of making a joint decision
between all combinations of treatments (e.g. between A,
B, neither or both) allowing for interactions, rather than
making separate decisions on treatments for the same pa-
tient group that assume no interaction [11]. We therefore
evaluated methods using an economic evaluation based
on a partial factorial trial, although similar issues also
apply to analyses of clinical endpoints.
We propose four methods that could be used to esti-
mate main effects in partial factorial trials, with or with-
out allowance for interactions:
1. At-the-margins analysis. Analysing each factor
separately (e.g. evaluating drug A in Table 1 by
comparing outcomes for the 130 patients in cells
a0, ab, a– and a+ with those for the 130 patients in
cells 00, 0b, 0– and 0+) may give a good indication
of population average effects for partial factorial
trials, although this approach is prone to bias when
there are interactions [12–14]. Several reviews on full
factorial trials argue that at-the-margins estimates of
the main effect of factor A may be informative even
in the presence of interactions if the ratio of B to
not-B in the trial reflects the ratio in the setting of
Table 1 Schematics of hypothetical full and partial factorial designs
Full factorial trial (n = 400)
Placebo of A Drug A Total
Placebo of B 100 pts. (00) 100 pts. (a0) 200 pts
Drug B 100 pts. (0b) 100 pts. (ab) 200 pts
Total 200 pts 200 pts
Partial factorial trial (n = 400)
Randomised in comparison A Not randomised in comparison A Total
Placebo of A Drug A Did not have A Received A
Randomised in comparison B Placebo of B 40 pts. (00) 40 pts. (a0) 30 pts. (−0) 40 pts. (+ 0) 150 pts
Drug B 40 pts. (0b) 40 pts. (ab) 28 pts. (−b) 42 pts. (+b) 150 pts
Not randomised in comparison B Did not have B 10 pts. (0–) 11 pts. (a–)
Received B 40 pts. (0+) 39 pts. (a+)
Total 130 pts 130 pts
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interest (e.g. routine clinical practice) [12, 15, 16].
While this is unlikely for many full factorial trials,
partial factorial trials enable the distribution of
patients between B and not-B to be governed by
routine clinical practice for those patients not
randomised to this comparison (although
conversely it is also possible that clinicians’ use of
B will be affected by whether patients are also
randomised to receive A). As a result, at-the-
margins analysis may give a good estimate of
average incremental effects across the whole population
for a partial factorial trial, even if there is an interaction.
2. Inside-the-table analysis. This focuses on the subset
of patients randomised to > 1 comparison and
analyses cells 00, a0, 0b and ab (Table 1) “inside-
the-table” like a full factorial trial. This analysis
ensures unbiased estimation of interactions, but it
excludes many patients (60% [240/400] in the case
of Table 1). Consequently, interactions can only be
evaluated on a small sample, and the power to
detect main effects is reduced. Furthermore, the
patients randomised to > 1 comparison may not be
representative of the whole trial population,
potentially reducing generalisability.
3. Bayesian bootstrap. This previously-described
technique [17, 18] could be used to update the
inside-the-table analysis on patients randomised
to > 1 comparison (cells 00, a0, 0b and ab in
Table 1) to take account of the additional information
provided by patients randomised to only one
comparison (cells 0–, 0+, a–, a+, − 0, + 0, −b
and + b). This approach uses the entire sample
“as-randomised”. Bayesian bootstrapping has
recently been applied to take account of external
evidence from other trials [18], but it has not previously
been applied to partial factorial studies.
4. Subgroup analysis. This analyses the entire trial
population “as-treated” and subdivides all patients
into ≥ 4 groups based on the combination of
treatments that they actually received. For example,
in Table 1 we might pool cells ab and a+. Inside-
the-table analysis can therefore be done by comparing
outcomes for the four combinations of received
treatment. However, this approach analyses patients
according to the treatment that they actually received
(rather than their randomised allocation) and is
therefore prone to the selection bias associated with
per protocol analysis [19]. Furthermore, since the
patients in cells 0–, 0+, a–, a+, − 0, + 0, −b and + b
are not randomly assigned to the second factor, any
observed effect of this second factor or any observed
interactions between the two factors could be caused
by confounding rather than causal effects. For
example, if we find that patients in cell 0+ have
worse outcomes than those in cell 0–, this could be
due to patient characteristics that both affected
outcomes and the probability of receiving treatment
B, rather than a causative effect of B. As such,
subgroup analysis of partial factorial trials carries
many of the same hazards and biases as analyses
of observational studies or subgroup analysis of
two- or three-arm trials [20, 21]. By contrast, full
factorial randomisation with intention-to-treat (ITT)
analysis and concealment of allocation avoids selection
bias and ensures that the only systematic difference
between randomised groups is the allocated treatment.
This study aims to explore the implications of partial
factorial design on the methods and results of economic
evaluation, illustrate the methods that can be applied
and compare how the results and conclusions of an ap-
plied example differ between at-the-margins analysis,
inside-the-table analysis on patients randomised to > 1
comparison and the Bayesian bootstrap. The subgroup
approach is presented in Additional file 1 due to the bias
inherent in this approach. Additional file 1 also summa-
rises the assumptions underpinning each analysis.
Methods
Case study
The Knee Arthroplasty Trial (KAT, International Standard
Randomised Trial No. ISRCTN45837371; see Additional
file 2) is a pragmatic partial factorial randomised trial evalu-
ating three2 aspects of knee prosthesis design [3, 5, 22]:
1. Bearing. Using a mobile bearing versus a fixed
bearing
2. Backing. Using a metal-backed tibial component
versus one made of solid polyethylene
3. Patella. Resurfacing the patella (i.e. replacing part of
the knee cap with plastic) versus no resurfacing
Patients about to undergo knee replacement were re-
cruited and randomised to those comparisons for which
the surgeon was in equipoise. The partial factorial design
enabled patients to be randomised to the patella com-
parison as well as either the bearing or backing com-
parison (Fig. 1). This design and recruitment strategy
was chosen to maximise recruitment of surgeons and
patients and to acknowledge the marked variations between
surgeons in the comparisons for which they are willing to
accept randomisation. Given that there was no previous evi-
dence on interactions and no clinical reason why one would
be expected (at least for the primary endpoint, Oxford knee
score), the primary clinical and economic analyses were
conducted at-the-margins [3]. This follows standard
practice for most factorial trials and would be orthodox
for any simple treatment-versus-no-treatment comparison
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in any randomised trial, even where interactions with sub-
groups were plausible.
Cost-utility analysis, calculating the cost per quality-
adjusted life year (QALY) gained, was conducted on re-
sults at a median of 10 years’ post-operation follow-up
[3] (see Additional file 1). Net monetary benefit (NMB =
QALYs ⋅ Rc ‐ cost) is reported at a £20,000/QALY ceiling
ratio (Rc) to reflect the amount that the National Health
Service (NHS) is typically willing/able to pay to gain one
QALY [23]. Costs are presented in 2011/2012 pounds.
Multiple imputation [24] was used to impute missing
data on utilities and resource use. To ensure a fair com-
parison, the same set of imputed values was used for all
analyses. Imputation was conducted on the entire trial
population rather than separately for each comparison
and assumed no interactions to match the base case ana-
lysis (see Additional file 1).
Bootstrapping was conducted to allow for uncertainty.
For Analyses 1, 2 and 4, we used 100 bootstraps on each
of the 100 imputed datasets and based point estimates
on the sample mean (with no bootstrapping or bias
correction); results for the 100 imputed datasets were
combined using Rubin’s rule [24] and used to estimate
standard errors (SEs), p values and cost-effectiveness ac-
ceptability curves (CEACs). The bootstrapping methods
used in Analysis 3 are described below.
With the exception of Analysis 3, all analyses were
conducted in Stata version 12. All p values are two-sided.
Analysis 1 (base case) methods: at-the-margins analysis
The base case analysis comprised at-the-margins analysis
to ensure consistency with the primary clinical analysis
and to take account of all participants as-randomised.
Furthermore, at-the-margins estimates are particularly
likely to reflect population average effects for KAT, since
patients were only randomised to the comparisons for
which surgeons were in equipoise, which implies that
treatment allocation would have been approximately 50:50
regardless of whether patients were randomised. For this
analysis, bootstrapping was conducted separately for each
of the three comparisons, including only those patients
randomised to that comparison.
Analysis 2 methods: inside-the-table analysis
Analysis 2 considered the subset of patients randomised
to > 1 comparison on an ITT basis like a small full factorial
trial. In this analysis, bootstrapping was conducted twice:
once on the 193 patients randomised to the bearing and
patella comparisons, and once on the 145 patients rando-
mised to the backing and patella comparisons. For each
bootstrap, linear regression was used to predict the costs
and QALYs accrued in each year of the trial:
AnnualCost ¼ β0 þ βAAþ βPatellaPatella þ βIntPatella  A
AnnualQALYs ¼ β0 þ βAAþ βPatellaPatellaþ βIntPatella  A
þβBaselineUtilityBaselineUtility
ð1Þ
where A indicates randomised allocation in the bearing
or backing comparisons, and Patella indicates whether
patients were randomised to patella resurfacing. The
interaction between treatment allocations was calculated
for total costs, total QALYs and NMB in each bootstrap
replicate (Interaction = μab − μa0 − μ0b + μ00, where μx in-
dicates the mean outcome in arm x).
Analysis 3 methods: Bayesian bootstrap
Bayesian bootstrapping involves weighting bootstrap sam-
ples based on a prior. This can be done using rejection
sampling, where the weights determine the probability that
a bootstrap sample is included in the analysis rather than
being rejected [18, 25]. We used this “vetted bootstrap”
technique to explore the interaction between interventions
in a partial factorial trial while taking account of the entire
sample, including the patients randomised to only one
comparison (who were excluded from inside-the-table
analysis).
We used the (posterior) evidence from the patients
randomised to one comparison as a prior that was up-
dated using the evidence from patients randomised to > 1
comparison. This was implemented by rejecting a propor-
tion of the bootstraps on patients randomised to > 1 com-
parison that had at-the-margins incremental NMB (INB)
estimates that were not consistent with the data on patients
randomised to one comparison. For simplicity, rejection
Fig. 1 Design of KAT (n = 2252, excluding patients who died/withdrew before surgery). Numbers and rectangular areas represent the number of
patients randomised to each arm. Adapted from Table 1 in Murray et al. [3]
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sampling was done using INB, which combines between-
group differences in costs and QALYs into a single metric
that reflects value for money. Costs, QALYs and NMB were
then calculated for the set of bootstraps that passed rejec-
tion sampling based on their INB. The analysis was done in
five steps (steps 1, 2a–c and 3).
Step 1: Estimate outcomes for patients randomised in
only one comparison that are used as priors for rejection
sampling in step 2b. Patients who were randomised in >
1 comparison were excluded from this analysis to ensure
that the priors were independent of the data that were
used to update them. We calculated the mean INB across
each of the three sets of patients randomised to only one
comparison ( INBAe =NMBA −NMBnotA for those patients
randomised only in comparison A, and similarly for INBBe
and INBCe). We then conducted standard bootstrap ana-
lyses on the same three samples, drawing 100 bootstrap
samples from each of the 100 imputed datasets. SEs
around mean INB (σAe, σBe and σCe) were then calculated
using Rubin’s rule [24].
Step 2a: Bootstrap samples of patients randomised to
> 1 comparison. We conducted a standard bootstrap on
the two sets of patients randomised to > 1 comparison,
conducting > 300 bootstraps per imputed dataset on the
patients randomised to the bearing and patella comparisons
and 750 bootstraps per imputed dataset for the patients
randomised to the backing and patella comparisons.3
Step 2b: Calculate weights for each bootstrap sample
from step 2a. The weights determine the probability that
this bootstrap sample would be included in the analysis.
The weights ω(INBA, INBC)
∗ comprise numbers between
0 and 1 that indicate how closely the INB for the current
bootstrap of patients randomised to > 1 comparison (INBA
and INBC ) matches the evidence (INBAe and INBCe) calcu-
lated on patients randomised to one comparison. We
followed [18] in assuming a Gaussian likelihood:
ω INBA; INBCð Þ ¼ exp − INBA
−INBAeð Þ2
2σ2Ae
−
INBC−INBCeð Þ2
2σ2Ce
 !
ð2Þ
Weights were based on INB, rather than costs or
QALYs, since allowing for the correlation between costs
and QALYs would have complicated the estimation of
weights. The calculation of weights takes advantage of
the fact that INB for patients randomised only to com-
parison A (INBAe) is independent of the INB for patients
randomised only to C (INBCe). The base case results
were based on rejection sampling using a £20,000/QALY
ceiling ratio, although this ceiling ratio was varied to
generate CEACs.
For a partial factorial trial, it is debatable whether weights
should be based on main effects (calculated at-the-margins,
e.g. as the average of a0 and ab in Table 1, minus the
average of 00 and 0b) or simple effects (calculated
inside-the-table, e.g. as a0 minus 00) for the patients
randomised in > 1 comparison. In this case, we felt that
the INB for patients randomised only to mobile versus
fixed bearing was more comparable to the at-the-margins
estimate of the INB for mobile versus fixed bearing for the
patients randomised to > 1 comparison, since both include
patients with a mixture of patella resurfacing and no re-
surfacing (and likewise for the other comparisons). How-
ever, the most appropriate approach should be decided on
a case-by-case basis, since in other situations (e.g. where
one of the treatments is not used at all in the patients
randomised to only one comparison), it might be more
appropriate to use the simple effect.
Step 2c: Use weights to determine which bootstraps
from step 2a are included in the analysis. The weights
were compared against numbers randomly drawn from a
uniform distribution, and those bootstraps with random
numbers greater than the weight were excluded from
the analysis. We considered each bootstrap independ-
ently; as a result, the analysis included more bootstraps
from some imputed datasets than others.
Step 3: Analyse the bootstraps passing the vetting. We
calculated the mean NMB, cost and QALYs for each
intervention by averaging across the bootstraps passing
rejection sampling. We developed a modified version of
Rubin’s rule (Eq. 3), which calculates standard errors
(
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
va^rðθ^Þ
q
) as the weighted average of the variance (va^
rðθ^mÞ) and the deviation from the overall mean (ðθ^m−θ^Þ2)
for each of the M imputed datasets, giving equal weight to
each bootstrap that passed the rejection sampling:
va^r θ^
 
¼ 1
MN
XM
m¼1
va^r θ^m
 
Nm þ 1þ 1M
 
1
MN−N
 XM
m¼1
θ^m−θ^
 2
Nm
ð3Þ
where Nm indicates the number of imputed datasets
passing rejection sampling in imputation m, while N
equals the average number of bootstraps included across
all M imputed datasets. The derivation is given in
Additional file 1.
Bayesian p values were based on the proportion of
included bootstraps with positive or negative values
for the parameter of interest. CEACs were based on
the proportion of bootstraps in which each treatment
combination had the highest NMB. Bootstrapping was
conducted in Stata version 14, while subsequent analyses
were conducted in Microsoft Excel 2010. Additional file 3
shows the methods used to estimate weights and vet boot-
straps in Excel. We conducted steps 2a–c sequentially,
conducting all bootstraps before determining which were
included in the analysis, although these steps may be done
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for each bootstrap in turn, discarding results for boot-
straps that did not pass the vetting.
Results
Analysis 1 (base case) results: at-the-margins analysis
Analysis 1 evaluated each of the three comparisons sep-
arately on all patients randomised to that comparison,
treating each comparison as an independent decision.
Comparing outcomes for all patients randomised to patella
resurfacing against all those randomised to no resurfacing
suggested that patella resurfacing dominated no resur-
facing, generating an additional 0.19 QALYs and saving an
average of £104 per patient treated with a 96% chance of
being cost-effective4 (Table 2, Additional file 1). On average,
mobile bearings were cost-effective compared with fixed
bearings, although QALY gains were very small and there
was substantial uncertainty around this finding. Ana-
lysis 1 also suggested that we can be 91% confident that
metal-backed components are cost-effective compared
with non-metal-backed ones, with an incremental cost-ef-
fectiveness ratio (ICER) of just £35 per QALY gained. If
we were to make separate decisions treating the different
aspects of knee component design as independent op-
tions, we might therefore recommend patella resurfacing,
metal backing and (more hesitantly) mobile bearing.
Analysis 2 results: inside-the-table analysis
Analysis 2 aimed to inform joint decisions between com-
binations of treatment strategies by analysing the subset
of patients randomised to > 1 comparison inside-the-table
as a full factorial trial. The analysis of mobile bearings and
patella resurfacing included 193 patients: 37% of those ran-
domised in the bearing comparison. The subset of patients
randomised to both comparisons tended to have higher
costs than the average patient in the bearing comparison,
and all SEs were at least twice as large as those in Analysis 1
due to the substantially smaller sample size (Tables 2 and 3).
Large, but not statistically significant, interactions
were observed for costs, QALYs and NMB (Table 4). All
three interactions were qualitative, with the incremental
costs, QALYs and NMB for mobile bearings changing
sign depending on whether patients were allocated to
patella resurfacing or no resurfacing (Table 3). In par-
ticular, patients randomised to mobile bearings with no
patella resurfacing accrued substantially higher costs and
substantially fewer QALYs than the other three groups.
Mobile bearings therefore dominated fixed bearings in pa-
tients who were also randomised to patella resurfacing, but
were dominated in patients randomised to no resurfacing.
However, making a joint decision about mobile bearings
and patella resurfacing based on this analysis and adopting
the treatment with the highest expected NMB nonetheless
suggested that mobile bearings with patella resurfacing
should be recommended — the same conclusion obtained
from at-the-margins analysis.
However, despite the smaller sample size, inside-the-table
analysis suggested that there is substantially less uncertainty
around this decision compared with at-the-margins analysis
because the expected NMB for mobile bearings with patella
resurfacing is much higher than that of the alternatives.
Table 2 Results of at-the-margins analysis for all three comparisons
Comparison A: mobile bearing
(n = 262) versus fixed bearing
(n = 255)
Comparison B: metal-backed
(n = 199) versus non-metal-backed
(n = 203)
Comparison C: Patella resurfacing
(n = 841) versus no resurfacing
(n = 830)
Treatment group
Cost £8998 (£310) £8235 (£272) £8785 (£161)
QALYs 5.007 (0.143) 5.219 (0.151) 5.297 (0.076)
NMBa £91,145 (£2968) £96,145 (£3112) £97,158 (£1551)
Control group
Cost £8913 (£405) £8225 (£344) £8889 (£211)
QALYs 4.956 (0.141) 4.926 (0.152) 5.110 (0.080)
NMBa £90,209 (£2938) £90,290 (£3144) £93,308 (£1662)
Difference
Cost £85 (£508) £10 (£440) –£104 (£269)
QALYs 0.051 (0.196) 0.293 (0.210) 0.187 (0.108)
NMBa £936 (£4087) £5854 (£4343) £3849 (£2235)
ICER (per QALY gained) £1666 £35 Dominant
Probability cost-effectivea 0.59 0.91 0.96
Probability cost-saving 0.42 0.47 0.64
Numbers in brackets are SEs
aAt a £20,000/QALY ceiling ratio
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Mobile bearing plus patella resurfacing had an 86% chance
of being cost-effective in this analysis (Fig. 2a), whereas
in Analysis 1, the probability of mobile bearings being
cost-effective was only 59%.
Inside-the-table analysis on the 145 patients rando-
mised to the metal backing and patella comparisons also
highlighted a statistically significant interaction for QALYs
and non-significant qualitative interactions for costs and
NMB (Table 4).
Both costs and QALYs were substantially higher in the
group randomised to no metal backing and no patella
resurfacing and the group randomised to metal backing
and patella resurfacing than in the other two groups
(Table 5). Furthermore, this analysis suggested that the
treatment with the highest NMB is all-polyethylene with
no patella resurfacing, with the opposite combination
(metal backing with patella resurfacing) coming a close
second. However, the subset of patients randomised in
both the backing and patella comparisons tended to ac-
crue lower costs and higher QALYs than those rando-
mised to just the backing comparison, suggesting that
this patient population may not be typical.
There was also substantial uncertainty around this
finding (Fig. 2b), with a 43% chance that metal backing
with patella resurfacing has the highest NMB and a 50%
chance that all-polyethylene with no patella resurfacing
is best.
Analysis 3 results: Bayesian bootstrap
Bayesian bootstrapping produced estimates of mean
costs, QALYs and NMB that were broadly similar to
those of Analysis 2, although SEs were lower in Analysis
3 for QALYs and NMB in all groups and for costs in
most groups (Tables 3 and 5). The magnitude of interac-
tions and their standard errors were similar to those for
inside-the-table analysis, and both analyses found all in-
teractions to be qualitative (Table 4).
Like Analyses 1 and 2, Bayesian bootstrapping found
mobile bearing with patella resurfacing to be the most
effective and best value for money intervention in the
bearing comparison, having the highest expected NMB
and highest mean QALYs. However, Bayesian bootstrap-
ping found metal backing with patella resurfacing to be
the most cost-effective option in the backing comparison.
This matches the results of at-the-margins analysis, but
contradicts the unexpected finding of inside-the-table ana-
lysis (which found all-polyethylene with no resurfacing to
have a slightly higher NMB than metal backing with
patella resurfacing).
CEACs demonstrated that Bayesian bootstrapping pro-
duced results with substantially less uncertainty around the
most appropriate treatment option than inside-the-table
Table 3 Results of comparison A (mobile versus fixed bearing)
for Analyses 2 and 3
Analysis 2: inside-the-table Analysis 3: Bayesian bootstrap
With patella resurfacing
Mobile bearing (N = 47)a
Cost £9068 (£466) £9112 (£468)
QALYs 5.559 (0.264) 5.471 (0.227)
NMBb £102,110 (£5372) £100,301 (£4612)
Fixed bearing (N = 51)a
Cost £9169 (£1165) £9382 (£1167)
QALYs 4.959 (0.289) 4.891 (0.240)
NMBb £90,015 (£6256) £88,443 (£5169)
No patella resurfacing
Mobile bearing (N = 52)a
Cost £11,100 (£1147) £10,930 (£1065)
QALYs 4.732 (0.311) 4.820 (0.251)
NMBb £83,533 (£6755) £85,475 (£5385)
Fixed bearing (N = 43)a
Cost £8481 (£464) £8416 (£460)
QALYs 5.029 (0.294) 5.135 (0.231)
NMBb £92,104 (£6014) £94,290 (£4703)
Numbers in brackets are SEs
aIn Analysis 3, the bootstraps were weighted using weights calculated using a
sample of 324 patients randomised only in the bearing comparison (163 to
mobile bearing and 161 to fixed bearing) and 1333 patients randomised only
in the patella comparison (673 to patella resurfacing and 660 to
no resurfacing)
bAt a £20,000/QALY ceiling ratio
Table 4 Magnitude of interactions in Analyses 2 and 3
Analysis 2: inside-the-table analysis Analysis 3: Bayesian bootstrapping
Comparison A: mobile versus fixed bearing
Interaction for cost (SE) –£2720 (£1751), p = 0.12 –£2784 (£1790), p = 0.09
Interaction for QALYs (SE) 0.90 (0.51), p = 0.08 0.89 (0.51), p = 0.08
Interaction for NMBa (SE) £20,667 (£10,820), p = 0.06 £20,672 (£11,029), p = 0.06
Comparison B: metal-backed versus all-polyethylene
Interaction for cost (SE) £506 (£907), p = 0.58 £475 (£890), p = 0.58
Interaction for QALYs (SE) 1.06 (0.54), p = 0.05 1.12 (0.53), p = 0.03
Interaction for NMBa (SE) £20,788 (£11,094), p = 0.06 £21,940 (£10,954), p = 0.05
aAt a £20,000/QALY ceiling ratio
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analysis, because the INB for the most cost-effective treat-
ment compared with the next best alternative was larger
with a smaller standard error. The probability that mobile
bearings with patella resurfacing are cost-effective was
above 86% at all ceiling ratios (Fig. 2c), indicating that there
is substantially less uncertainty around this conclusion in
this analysis than was suggested by Analyses 1 or 2. The
probability that metal backing with patella resurfacing was
cost-effective was also above 94% at all ceiling ratios
above £10,000/QALY gained (Fig. 2d), in stark contrast
to inside-the-table analysis, where there was substantial
uncertainty about whether the best treatment was metal
backing with patella resurfacing or all-polyethylene with
no resurfacing (Fig. 2b).
Discussion
In this paper, we have developed and evaluated three
methods for estimating interactions within partial factorial
trials and compared them with at-the-margins analysis.
Each analysis provided different estimates of incremental
costs, QALYs and NMB. Conclusions for the backing
comparison also varied between analyses: inside-the-table
analysis suggested that all-polyethylene with no patella
resurfacing was best, whereas at-the-margins analysis,
Bayesian bootstrapping and the subgroup analysis (described
in Additional file 1) found metal backing with patella
resurfacing to be best.
Analysing the subset of patients randomised to > 1
comparison, inside-the-table (Analysis 2) provides an
unbiased estimate of interactions, since patients are ana-
lysed in the groups to which they were randomised, en-
suring that there is no systematic difference between
groups other than the treatment they received. However,
by restricting analysis to those in > 1 comparison, this
analysis included only 15% of the KAT trial population,
greatly increasing SEs and substantially reducing the
power to detect differences between treatment groups.
Furthermore, the subset of patients included in > 1 com-
parison may not be typical of the overall trial population.
In this case, patients who were in both the backing and
patella comparisons tended to accrue lower costs and
higher QALYs than those randomised to one compari-
son, with the opposite trends among patients in the
bearing and patella comparisons. Consequently, the in-
teractions observed in these patient subgroups may not
generalise to the wider population, and the unexpected
finding that all-polyethylene and no patella resurfacing
has the highest NMB could be spurious or due to
chance. However, inside-the-table analysis may have
greater power and greater generalisability in trials that
a b
c d
Fig. 2 CEACs for multiple comparisons allowing for interactions
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randomise a greater proportion of patients to > 1 com-
parison than was the case in KAT.
At-the-margins analysis (Analysis 1) may provide a
useful estimate of average costs and benefits for the
population of interest even when interactions exist. This
is particularly relevant to KAT, since decisions about
those aspects of implant design that were not randomly
assigned reflected routine clinical practice, and patients
were randomised only to those comparisons about which
surgeons were in equipoise. Indeed, the proportion of pa-
tients having patella resurfacing in KAT (50%) was similar
to that in routine clinical practice (39% [26]). Further-
more, at-the-margins analysis is simple to conduct and
explain, and it maximises statistical power by analysing
the entire trial population. However, by ignoring interac-
tions, at-the-margins analysis gives biased estimates of the
effect of each treatment in isolation [13]: in this case, the
bias in NMB estimates (equal to half the size of the inter-
action term [13]) was around £10,000, which is up to ten
times larger than the main effects. Furthermore, if the
interaction between metal backing and patella resurfacing
observed in inside-the-table analysis were genuine (i.e. if
all-polyethylene with no patella resurfacing truly has a
higher NMB than metal backing with patella resurfacing),
ignoring this interaction and basing decisions on at-the--
margins analysis would fail to maximise health gains from
the budget.
Bayesian bootstrapping (Analysis 3) overcomes the
drawbacks of the other three techniques, using all of the
data, analysing patients as-randomised and avoiding bias
by taking account of interactions. This approach assumes
that the evidence collected in patients randomised to one
comparison is applicable to patients randomised to > 1
comparison, although in principle it would be possible to
down-weight the evidence from the former group. In par-
ticular, evidence from patients randomised only in compari-
son A (for whom treatment B was not randomly allocated)
is used to vet the bootstraps before we estimate outcomes
for comparison B, although outcomes are always analysed
as-randomised. This is similar to using external evidence
from an A-versus-no-A trial alongside a factorial trial on A
and B. It may therefore be prudent to present a sensitivity
analysis using inside-the-table or at-the-margins analysis
alongside Bayesian bootstrapping — especially for regula-
tory submissions. Bayesian methods also enable interactions
to be down-weighted using sceptical priors [27, 28],
providing a compromise between including or exclud-
ing interaction terms. Rejection sampling is a useful
way to implement the Bayesian bootstrap for economic
evaluations, since it facilitates estimation of CEACs. How-
ever, importance sampling [18, 25], whereby a weighted
average is calculated across the bootstraps rather than
rejecting a proportion of bootstraps, may be more con-
venient and computationally faster when analysing clinical
endpoints from partial factorial trials.
Although the subgroup analysis presented in Additional
file 1 (Analysis 4) considered all patients, it required
the patella comparison to be analysed as-treated, not
as-randomised, which introduced selection bias. Con-
sequently, the markedly smaller interactions observed
in this analysis may be due to, or confounded by, patient
characteristics (e.g. age, physical activity or severity of
bone damage) that affect whether surgeons undertake pa-
tella resurfacing as well as the costs and QALYs accrued
over the time horizon.5 This analysis therefore does not
inform causal inferences about the main effect of patella
resurfacing or interactions between factors and is not an
appropriate way to evaluate or control for interactions in
partial factorial trials.
This study suggests that there is evidence that patella
resurfacing may affect the incremental costs, QALYs and
cost-effectiveness of mobile bearings and metal backing.
Interactions were generally qualitative (changing the
direction of incremental effects). Although interactions
were not expected a priori, it is plausible that since pa-
tella resurfacing, mobile bearings and metal backing can
influence knee kinematics, interactions could occur that
might affect patients’ quality of life and/or their risk of
Table 5 Results of comparison B (metal-backed versus all-
polyethylene) for Analyses 2 and 3
Analysis 2: inside-the-table Analysis 3: Bayesian bootstrap
With patella resurfacing
Metal backing (N = 34)a
Cost £8036 (£411) £7925 (£391)
QALYs 5.518 (0.337) 5.820 (0.248)
NMBb £102,327 (£6870) £108,467 (£5041)
All-polyethylene (N = 36)a
Cost £7833 (£567) £7849 (£550)
QALYs 5.046 (0.330) 4.989 (0.262)
NMBb £93,087 (£6837) £91,940 (£5416)
No patella resurfacing
Metal backing (N = 37)a
Cost £7782 (£384) £7749 (£357)
QALYs 4.976 (0.311) 5.117 (0.258)
NMBb £91,745 (£6348) £94,586 (£5255)
All-polyethylene (N = 38)a
Cost £8085 (£409) £8148 (£409)
QALYs 5.569 (0.248) 5.407 (0.220)
NMBb £103,293 (£5031) £99,999 (£4451)
Numbers in brackets are SEs
aIn Analysis 3, the bootstraps were weighted using weights calculated using a
sample of 257 patients randomised only in comparison B (128 to metal
backing and 129 to all-polyethylene) and 1333 patients randomised only in
comparison C (673 to patella resurfacing and 660 to no resurfacing)
bAt a £20,000/QALY ceiling ratio
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readmission. However, the exact form of the interactions
is difficult to explain clinically: for example, it is unclear
why all-polyethylene with patella resurfacing should pro-
duce fewer QALYs than either metal backing with patella
resurfacing or all-polyethylene without resurfacing. KAT
was not designed or powered to estimate interactions;
generally interactions need to be twice as large as the
predicted main effect to be detected with the same stat-
istical power [14]. Furthermore, the observed interac-
tions could be due to chance, since only three of the 18
interaction terms estimated were statistically significant
at the 0.05 level. Nonetheless, such interactions may
warrant further investigation. The present study is the
first methodological work conducted on partial factorial
trials and applies methods to a particular dataset, but
further work simulating a variety of plausible scenarios
would add to our understanding of the use and analysis
of partial factorial designs and help to evaluate the ana-
lytical methods in datasets where the “true” interaction
is known.
Conclusions
This study demonstrates that partial factorial trials can
be used to evaluate interactions. Such trials are more
informative and cheaper than conducting two separate
trials on non-overlapping populations. However, com-
pared with full factorials, a partial factorial design reduces
the size and generalisability of the sample available for
evaluating interactions. Nonetheless, a partial factorial de-
sign may substantially increase recruitment in situations
where not all patients can be randomised to > 1 compari-
son, thereby increasing the size and generalisability of the
sample available for at-the-margins analysis with little/no
impact on the number randomised to > 1 comparison.
Nonetheless, given the difficulties evaluating interactions,
partial factorial designs may be best reserved for situations
where interactions are expected to be negligible.
The choice of analysis may depend on the decision-
maker’s research question and the impact of interactions.
At-the-margins analysis may provide a useful estimate of
average treatment effects for pragmatic partial factorial
trials in which the proportion of patients receiving each
treatment is likely to be similar to that in routine clinical
practice. Nonetheless, at-the-margins analysis is prone
to bias and potentially misleading conclusions whenever
interactions exist [10, 12–14], so the impact of interac-
tions should always be evaluated in sensitivity analysis.
Furthermore, unlike the other methods, at-the-margins
only estimates main effects and does not provide any
information on interactions. For economic evaluation, it
is generally more appropriate to make a joint decision
about which combination of treatments provides the
best value for money, taking account of any interactions
[10, 11]. Such decisions are facilitated by inside-the-table
analysis and Bayesian bootstrapping, whereas at-the-margins
analysis implicitly assumes no interaction and only in-
forms separate decisions on each factor.
Bayesian bootstrapping may be the most appropriate
way to evaluate interactions in partial factorial trials,
although conducting inside-the-table analysis on patients
randomised to > 1 comparison may provide a simple
method for conducting sensitivity analysis, particularly
for studies where most patients are randomised to > 1
comparison. Evaluating interactions on the total sample
by subgrouping patients by the treatment they receive is
inappropriate, as it breaks randomisation and is prone to
bias.
The principles and methods developed here for eco-
nomic endpoints could also be applied to analyses of any
outcome measure to assess the magnitude of interac-
tions and the extent to which the results are sensitive to
interactions.
Endnotes
1We follow the definition used by [1–3], although the
term “partial factorial trials” is also used to describe “in-
complete factorial trials” in which all experimental units
are randomised to a subset of the possible combinations
of factors [12, 29].
2A fourth factor was also evaluated [3], comparing
total versus unicompartmental knee replacement, but it
is not discussed here since it did not overlap with other
comparisons and stopped early due to difficulties in
recruiting participants.
3This number of bootstraps was chosen for pragmatic
reasons and ensured that after rejection sampling there
were at least 6000 bootstraps included in the analysis at
a £20,000/QALY ceiling ratio, although the exact number
of bootstraps included in the calculation of CEACs varied
with ceiling ratio.
4Notably, this analysis provides a real-life example of
the situation identified hypothetically previously [30, 31],
in which NMB differs significantly (p = 0.96 on a one-tailed
test) between treatments, despite non-significant differences
in both costs and effects.
5In principle, we could reduce bias by adjusting for
observed confounders (e.g. using propensity scores or
genetic matching [32, 33]), although the subgroup
approach would remain vulnerable to bias from unobserved
confounders.
Additional files
Additional file 1: Additional information on assumptions, methods,
acceptability curves, methods and results of the inside-the-table sub-
group analysis (DOCX 190 kb)
Additional file 2: CONSORT checklist and flowcharts for the KAT trial.
(DOCX 42 kb)
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Additional file 3: Spreadsheet demonstrating the methods used to vet
bootstraps. Gives the formulae used to estimate weights, vet the
bootstraps and analyse results, using a small number of hypothetical
bootstraps that would normally be generated in another software
package (e.g. Stata). (XLSX 422 kb)
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